ethyl (-)-(R,R)-2-(4-aminophenyl)cyclopropanecarboxylate | 853403-99-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl (-)-(R,R)-2-(4-aminophenyl)cyclopropanecarboxylate
• 英文别名: ethyl (1R,2R)-2-(4aminophenyl)cyclopropanecarboxylate；ethyl (1R,2R)-2-(4-aminophenyl)cyclopropanecarboxylate；ethyl (1R,2R)-2-(4-aminophenyl)cyclopropane-1-carboxylate
• CAS: 853403-99-3
• 化学式: C₁₂H₁₅NO₂
• 分子量: 205.257
• InChiKey: PRQHGNILEBKMGD-WDEREUQCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl (-)-(R,R)-2-(4-aminophenyl)cyclopropanecarboxylate 在 sodium hydroxide 、 Na(OAc)3H 作用下， 以 四氢呋喃 、 乙醇 、 1,2-二氯乙烷 为溶剂， 生成 (+)-(trans)-2-{4-[(3-Phenoxybenzyl)amino]phenyl}cyclopropanecarboxylic acid
  参考文献：
  名称：

  Synthesis and activity of small molecule GPR40 agonists

  摘要：

  The first report on the identification and structure-activity relationships of a novel series of GPR40 agonists based on a 3(4-{[N-alkyl]amino phenyl)propanoic acid template is described. Structural modifications to the original screening hit yielded compounds with a 100-fold increase in potency at the human GPR40 receptor and pEC(50)s in the low nanomolar range. The carboxylic acid moiety is not critical for activity but typically elicits an agonistic response higher than those observed with carboxamide replacements. These compounds may prove useful in unraveling the therapeutic potential of this receptor for the treatment of Type 2 diabetes. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.007
• 作为产物：
  描述：

  重氮乙酸乙酯 、 4-硝基苯乙烯 在 platinum(IV) oxide (CuOTf)*toluene 、 2,2'-diisopropylidenebis[(4S)-4-tert-butyl-2-oxazoline] 、 氢气 作用下， 以 氯仿 、 乙醇 为溶剂， 20.0 ℃ 、344.74 kPa 条件下， 生成 环丙羧酸,2-(4-硝基苯基)-,乙基酯,(1R,2R)-rel- 、 ethyl (-)-(R,R)-2-(4-aminophenyl)cyclopropanecarboxylate
  参考文献：
  名称：

  Synthesis and activity of small molecule GPR40 agonists

  摘要：

  The first report on the identification and structure-activity relationships of a novel series of GPR40 agonists based on a 3(4-{[N-alkyl]amino phenyl)propanoic acid template is described. Structural modifications to the original screening hit yielded compounds with a 100-fold increase in potency at the human GPR40 receptor and pEC(50)s in the low nanomolar range. The carboxylic acid moiety is not critical for activity but typically elicits an agonistic response higher than those observed with carboxamide replacements. These compounds may prove useful in unraveling the therapeutic potential of this receptor for the treatment of Type 2 diabetes. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.007

文献信息

• [EN] HETEROCYCLIC UREA COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES D'URÉE
  申请人：BIOTA EUROPE LTD

  公开号：WO2013091011A1

  公开（公告）日：2013-06-27

  The present invention provides a compound of the following formula, racemates, enantiomers and salts thereof. Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

  本发明提供了以下式的化合物，它们的外消旋体、对映体和盐。还提供了这些化合物作为抗菌剂的用途，包括它们的组合物和制造过程。
• [EN] AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40<br/>[FR] ACIDES AMINOPHENYLCYCLOPROPYLCARBOXYLIQUES ET LEURS DERIVES SERVANT D'AGONISTES DE GPR40
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005051890A1

  公开（公告）日：2005-06-09

  The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation.

  本发明一般涉及新型治疗化合物，更具体地涉及新型化合物，它们作为GPR40激动剂的用途，它们的制造工艺以及在它们的制备中有用的中间体。
• AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40
  申请人：Corbett David Francis

  公开号：US20090105257A1

  公开（公告）日：2009-04-23

  The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation.

  本发明通常涉及新型治疗化合物，更特别地涉及新型化合物，其用作GPR40激动剂，其制造过程以及其制备中有用的中间体。
• Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
  申请人：GlaxoSmithKline LLC

  公开号：US07834013B2

  公开（公告）日：2010-11-16

  The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation.

  本发明一般涉及新型治疗化合物，更具体地涉及新型化合物，其作为GPR40激动剂的用途，其制造过程以及在其制备中有用的中间体。
• Heterocyclic urea compounds
  申请人：BIOTA EUROPE LTD

  公开号：US09060515B2

  公开（公告）日：2015-06-23

  The present invention provides a compound of the following formula, racemates, enantiomers and salts thereof. Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

  本发明提供以下公式的化合物，外消旋体，对映体和其盐。还提供这些化合物作为抗菌剂的用途，包含它们的组合物和制造它们的过程。